MX382484B - Una dieta para usarse en la reducción de niveles de glucosa y/o igf-1. - Google Patents
Una dieta para usarse en la reducción de niveles de glucosa y/o igf-1.Info
- Publication number
- MX382484B MX382484B MX2015010320A MX2015010320A MX382484B MX 382484 B MX382484 B MX 382484B MX 2015010320 A MX2015010320 A MX 2015010320A MX 2015010320 A MX2015010320 A MX 2015010320A MX 382484 B MX382484 B MX 382484B
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- protein
- levels
- intake
- age related
- Prior art date
Links
- 235000005911 diet Nutrition 0.000 title 1
- 230000037213 diet Effects 0.000 title 1
- 235000021075 protein intake Nutrition 0.000 abstract 3
- 101001081567 Homo sapiens Insulin-like growth factor-binding protein 1 Proteins 0.000 abstract 2
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 2
- 102100027636 Insulin-like growth factor-binding protein 1 Human genes 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000021439 fasting mimicking diet Nutrition 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Pediatric Medicine (AREA)
- Analytical Chemistry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361763797P | 2013-02-12 | 2013-02-12 | |
| PCT/US2014/016025 WO2014127000A2 (en) | 2013-02-12 | 2014-02-12 | Methods and diets to protect against chemotoxicity and age related illnesses |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015010320A MX2015010320A (es) | 2016-06-02 |
| MX382484B true MX382484B (es) | 2025-03-13 |
Family
ID=51297596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015010320A MX382484B (es) | 2013-02-12 | 2014-02-12 | Una dieta para usarse en la reducción de niveles de glucosa y/o igf-1. |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9237761B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2956776A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6885671B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20150124962A (cg-RX-API-DMAC7.html) |
| CN (3) | CN114236130A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2014216349B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015019223A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2900782C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2807781T3 (cg-RX-API-DMAC7.html) |
| MX (1) | MX382484B (cg-RX-API-DMAC7.html) |
| RU (2) | RU2018141475A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014127000A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10015980B2 (en) | 2012-10-22 | 2018-07-10 | University Of Southern California | Methods and formulations promoting tissue/organ regeneration, longevity and healthspan |
| KR20150124962A (ko) * | 2013-02-12 | 2015-11-06 | 유니버시티 오브 써던 캘리포니아 | 화학 독성 및 연령 관련 질병으로부터 보호하기 위한 방법 및 규정식 |
| MX381340B (es) | 2013-07-01 | 2025-03-12 | Univ Southern California | Dieta para diabetes basada en sistema de ayuno. |
| US10172839B2 (en) | 2014-03-06 | 2019-01-08 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| CA2944479C (en) | 2014-04-02 | 2023-02-21 | University Of Southern California | Dietary formulation and method for treating autoimmune and inflammatory diseases |
| BR112017017182A2 (pt) | 2015-02-12 | 2018-04-03 | Univ Southern California | composto para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, igf-1 e/ou socs e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; compostos para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, socs, igf-1 e insulina e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; método para tratamento de doenças ou condições com alterações em genes da sinalização relacionados com gh, ghr, stat5 e socs humanos; e método para tratamento de doenças ou condições causadas por atividade de hormônios do crescimento |
| US20160303056A1 (en) * | 2015-04-16 | 2016-10-20 | University Of Southern California | Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone |
| BR112017023748A2 (pt) * | 2015-05-06 | 2018-07-31 | University Of Southern California | métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso |
| WO2017097865A1 (en) * | 2015-12-07 | 2017-06-15 | Istituto Europeo Di Oncologia | Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor |
| CA3009664C (en) * | 2016-01-12 | 2024-02-13 | University Of Southern California | Use of long-term fasting mimicking as dietary treatment for multiple myeloma and other cancers |
| AU2017219732B2 (en) | 2016-02-15 | 2022-01-20 | University Of Southern California | Drug combinations and methods to stimulate embryonic-like regeneration to treat diabetes and other diseases |
| EP3454867B1 (en) | 2016-05-11 | 2021-03-24 | University of Southern California | Fasting mimicking diet (fmd) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases |
| IT201700008499A1 (it) * | 2017-01-26 | 2018-07-26 | Univ Degli Studi Genova | Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio |
| US11284640B2 (en) * | 2017-02-14 | 2022-03-29 | University Of Southern California | Fasting mimicking diet |
| CN112153974A (zh) | 2018-03-15 | 2020-12-29 | 南加利福尼亚大学 | 禁食模仿膳食(fmd)而非仅饮水禁食促进炎症和ibd病理学的逆转 |
| US20210267250A1 (en) | 2018-07-18 | 2021-09-02 | Andreas Michalsen | Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer |
| JP2020059699A (ja) * | 2018-10-04 | 2020-04-16 | 株式会社明治 | 難治性癌の食事療法およびそれに適した治療食 |
| BR112021008998A2 (pt) | 2018-11-09 | 2021-08-10 | L-Nutra | barra alimentar para simulação de jejum intermitente |
| CN114096164A (zh) | 2019-04-30 | 2022-02-25 | 南加利福尼亚大学 | 作为阿尔茨海默病(ad)的干预措施的禁食模拟饮食(fmd) |
| IT201900009954A1 (it) * | 2019-06-24 | 2020-12-24 | Fondazione Irccs Istituto Naz Dei Tumori | Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie |
| CN112273641A (zh) * | 2019-07-23 | 2021-01-29 | 中国科学院上海营养与健康研究所 | 一种非节食性的高低蛋白食物交替使用有效干预糖尿病的方法 |
| US20230037534A1 (en) * | 2019-12-16 | 2023-02-09 | University Of Southern California | Utilization of a fasting-mimicking diet to reduce senescent cells and inflammation |
| EP4076458A1 (en) | 2019-12-19 | 2022-10-26 | Leibniz-lnstitut Für Altersforschung | Nad-precursors and dietary restriction for treating age-related medical conditions |
| IT202000008740A1 (it) * | 2020-04-23 | 2021-10-23 | L Nutra Inc | Composizione dietetica per l’incremento della massa magra e della massa muscolare |
| US12029231B2 (en) * | 2020-07-13 | 2024-07-09 | L-Nutra Inc. | Method for the treatment of depression |
| IT202000016957A1 (it) | 2020-07-13 | 2022-01-13 | Univ Degli Studi Di Palermo | Composizione dietetica per il trattamento della depressione |
| US20230329304A1 (en) * | 2020-09-23 | 2023-10-19 | Aminovita S.L. | Metabolic therapy of cancer |
| TW202227113A (zh) | 2020-12-01 | 2022-07-16 | 南加州州立大學 | 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活 |
| CN114631629A (zh) * | 2020-12-15 | 2022-06-17 | 中国科学院上海营养与健康研究所 | 一种低蛋白治疗肥胖的方法 |
| CN114631628A (zh) * | 2020-12-15 | 2022-06-17 | 中国科学院上海营养与健康研究所 | 一种增加血液fgf21浓度的方法 |
| CN114794487A (zh) * | 2021-01-22 | 2022-07-29 | 中国科学院上海营养与健康研究所 | 一种治疗糖尿病的方法 |
| US20250177466A1 (en) * | 2022-08-23 | 2025-06-05 | University Of Southern California | Dietary compositions to extend longevity while maximizing strength and function |
| US20250194656A1 (en) * | 2023-12-14 | 2025-06-19 | L-Nutra Inc. | Longevity extending consumable products for maximizing strength and function, methods of consumption and manufacture |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406853B1 (en) * | 1999-12-23 | 2002-06-18 | The Regents Of The University Of California | Interventions to mimic the effects of calorie restriction |
| KR20040026665A (ko) * | 2001-06-15 | 2004-03-31 | 인터레우킨 제네틱스, 인코포레이티드 | 노화 관련 증상의 조기 개시를 검출 및 치료하는 방법 |
| US20040081678A1 (en) * | 2002-08-09 | 2004-04-29 | Anthony Cincotta | Therapeutic process for the treatment of obesity and associated metabolic disorders |
| US20050031671A1 (en) * | 2003-08-06 | 2005-02-10 | James Johnson | Weight management, longevity and health paradigm |
| US20100022451A1 (en) * | 2004-12-27 | 2010-01-28 | Nestec S.A. | Use of infant formula with reduced protein content |
| WO2007088046A2 (en) * | 2006-02-01 | 2007-08-09 | Nestec S.A. | Nutritional system and methods for increasing longevity |
| ES2800327T3 (es) * | 2008-04-24 | 2020-12-29 | Univ Of Southern California Usc Stevens | Composiciones dietéticas y métodos de protección contra la quimioterapia o radioterapia |
| CN101385543A (zh) * | 2008-10-23 | 2009-03-18 | 上海交通大学 | 低蛋白食品及其制备方法 |
| PL2490684T3 (pl) * | 2009-10-22 | 2018-07-31 | University Of Southern California | Sposoby i formulacje odżywcze dla zwiększenia skuteczności i zmniejszenia skutków ubocznych leczenia nowotworu |
| US10015980B2 (en) * | 2012-10-22 | 2018-07-10 | University Of Southern California | Methods and formulations promoting tissue/organ regeneration, longevity and healthspan |
| KR20150124962A (ko) * | 2013-02-12 | 2015-11-06 | 유니버시티 오브 써던 캘리포니아 | 화학 독성 및 연령 관련 질병으로부터 보호하기 위한 방법 및 규정식 |
-
2014
- 2014-02-12 KR KR1020157024630A patent/KR20150124962A/ko not_active Ceased
- 2014-02-12 CN CN202111523134.8A patent/CN114236130A/zh active Pending
- 2014-02-12 ES ES19160815T patent/ES2807781T3/es active Active
- 2014-02-12 BR BR112015019223A patent/BR112015019223A2/pt not_active Application Discontinuation
- 2014-02-12 CN CN201480008545.5A patent/CN105008929B/zh active Active
- 2014-02-12 RU RU2018141475A patent/RU2018141475A/ru unknown
- 2014-02-12 CN CN201811023405.1A patent/CN109187991B/zh active Active
- 2014-02-12 EP EP14751117.4A patent/EP2956776A4/en not_active Ceased
- 2014-02-12 EP EP19160815.7A patent/EP3510875B1/en active Active
- 2014-02-12 RU RU2015134780A patent/RU2674681C2/ru active
- 2014-02-12 AU AU2014216349A patent/AU2014216349B2/en active Active
- 2014-02-12 WO PCT/US2014/016025 patent/WO2014127000A2/en not_active Ceased
- 2014-02-12 JP JP2015557219A patent/JP6885671B2/ja active Active
- 2014-02-12 US US14/178,953 patent/US9237761B2/en active Active
- 2014-02-12 CA CA2900782A patent/CA2900782C/en active Active
- 2014-02-12 MX MX2015010320A patent/MX382484B/es unknown
-
2016
- 2016-01-15 US US14/996,946 patent/US20160331016A1/en not_active Abandoned
- 2016-10-20 US US15/298,963 patent/US20170035094A1/en not_active Abandoned
-
2019
- 2019-09-30 JP JP2019179570A patent/JP2020073473A/ja active Pending
-
2020
- 2020-01-15 AU AU2020200297A patent/AU2020200297B2/en active Active
-
2022
- 2022-04-27 AU AU2022202764A patent/AU2022202764A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX382484B (es) | Una dieta para usarse en la reducción de niveles de glucosa y/o igf-1. | |
| Passarino | NLO inspired effective Lagrangians for Higgs physics | |
| Mattes | Energy intake and obesity: ingestive frequency outweighs portion size | |
| NZ715431A (en) | Fasting condition as dietary treatment of diabetes | |
| MX2016012896A (es) | Autoinmunidad y tratamiento de la esclerosis multiple. | |
| WO2015091789A3 (en) | Nutritional composition for use in reducing metabolic stress in infants, decreasing gut permeability and approximating growth rate of breast-fed infants | |
| Ayo et al. | Heat stress, haematology and small intestinal morphology in broiler chickens: insight into impact and antioxidant-induced amelioration | |
| MX356263B (es) | Metodos para el manejo de la perdida de peso y la masa corporal. | |
| Thibault | Animal models of dietary-induced obesity | |
| Heydari et al. | Is gastric residual volume monitoring in critically ill patients receiving mechanical ventilation an evidence-based practice? | |
| PH12015502100A1 (en) | Reducing the risk of autoimmune disease | |
| Whiting et al. | Nutrition and lifestyle effects on vitamin D status | |
| Pradhan et al. | Food transitions in last 50 years and related environmental implications | |
| Sahi et al. | Oxidative stress in relation to obesity in Gujrati and non Gujarati young girls before and after maize diet. | |
| Gregory et al. | Trends in Creutzfeldt-Jakob Disease: The Mayo Clinic Experience 1976-2013: S709. | |
| Choi et al. | HOW CONSUMERS PROCESS RISK-AVOIDANCE APPEALS IN FOOD ADVERTISING: MODERATING ROLES OF FOOD HEALTHINESS AND DIETING STATUS ON THE PREDICTION MODEL OF SELF-AND FUNCTIONAL CONGRUITY | |
| Murphy et al. | Regular consumption of lean fresh pork has no adverse effect on body composition | |
| Jacob | Sudden death sydrome in poultry | |
| Strashynska | The main criteria for assessing the level of food security of a state | |
| Moon | White Rice Raised Diabetes Risk 17%, Over Brown Rice | |
| Oksamytna | Subjective Perception of Social Mobility: International Research Experience and Trends in Ukraine | |
| Boylan et al. | Patterns of overweight and obesity in Irish adults: 27/928. Nutrition and Healthy Lifestyle | |
| Department of Veterans Affairs | Copayments for medications in 2013. Final rule | |
| Meneton et al. | Dietary sources and correlates of sodium and potassium intakes in the French general population | |
| Pasqualetti | Rhabdomyolysis in an elderly patient: case report |